THE ISSUES OF DRUG INTERACTION IN COMBINATION PHARMACOTHERAPY IN CARDIOLOGICAL PRACTICE
Background. The objective of this study was to analyze the frequency and structure of appointment of undesirable combinations of statins with other drugs. We have taken into account their interactions at the level of metabolism CYP3A isoenzymes of cytochrome P450 and transportation of proteins-transporters P-glycoprotein and ОАТР1В to identify significant and potentially dangerous drug combinations.
Materials and methods. The study included medical records of people with diagnosis: Coronary heart disease with concomitant hypercholesterolemia, confirmed by laboratory methods. In total, we analyzed 2790 outpatients. The prevalence and structure of drug interactions at 14 medical institutions of Semey city (Kazakhstan) were studied (pharmacoepidemiological, cross-sectional study).
Results. Our study revealed the presence of significant and potentially dangerous interactions of statins with other drugs fr om the cardiovascular group in the majority of patients (62%). In cases wh ere it is recommended to prescribe combinations of drugs for clinical indications with caution and under the control of biochemical and other indicators, we found no evidence of this control in 72.5% of cases.
Conclusion. We have determined a fairly high frequency of the prescription of undesirable combinations of statins with other drugs from the cardiovascular group, having a competitive metabolism at the level of CYP3A, OATP1B1 and P-glycoprotein in absolute terms and compared with the data of studies conducted in developed countries.
Raikhan Ye. Tuleutayeva1, https://orcid.org/0000-0002-0462-5230
Assem R. Makhatova1, https://orcid.org/0000-0003-4127-7279
Аigerim Ye. Kassymkan1, https://orcid.org/0000-0002-0114-5397
Akzhan B. Zhumatay1, https://orcid.org/0000-0003-4558-5316
Assel Ye. Kakytayeva1, https://orcid.org/0000-0003-1943-5859
1 Pharmacology Department named after Dr. of medical sciences, Professor M. Mussin NJSC «Semey Medical University», Semey, Republic of Kazakhstan.
1. Ayrton A., Morgan P. Role of transport proteins in drug absorption, distribution and excretion // Xenobiotica. 2001. 31. 469-497. https://doi.org/10.1080/00498250110060969.
2. Bellosta S., Corsini A. Statin drug interactions and related adverse reactions: an update // Expert Opin Drug Saf. 2018. 17(1):25-37.doi:10.1080/14740338.2018.1394455
3. Bellosta. S., Corsini, A., Statin drug interactions and related adverse reactions // Expert Opin Drug Saf. 2012. 11(6):933-946.doi:10.1517/14740338.2012.712959
4. Boyd R.A., Stern R.H., Stewart B.H., Wu X., Reyner E.L., Zegarac E.A., Randinitis E.J., Whitfield L., Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion // J Clin Pharmacol. 2000. 40(1):91-98.
5. Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J., Drexel H. et al. ESC/EAS Guidelines for the Management of Dyslipidaemias // Eur. Heart J. 2016. 37, 39. 2999–3058. https://doi.org/10.1093/eurheartj/ehw272
6. Dua P., Zhao P., Zhang L. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs) // Eur J Drug Metab Pharmacokinet. 2017. 42(4): 689-705.doi:10.1007/s13318-016-0383-9.
7. Fernandes V., Santos M.J., Pérez A. Statin-related myotoxicity // Endocrinol Nutr. 2016. 63(5):239-49. doi:10.1016/j.endonu.2016.01.001.
8. Franz C.C., Bruggisser M., Krähenbühl S., Rätz Bravo A.E., Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole // Praxis. 2011. 2; 100 (5):273-84. doi:10.1024/1661-8157/a000491
9. Guemara R., Lazarou I., Guerne I.A. Drug-induced myopathies. Rev Med Suisse. 2017.13(562):1013-1017
10. Harolds J.A. Quality and Safety in Health Care, Part XXXIV: Coronary Artery Disease Secondary Prevention Medications // ClinNucl Med. 2018. 43(5). 331-332. doi:10.1097/RLU.0000000000001900
11. Heller D.J., Coxson P.G., Penko J., Pletcher M.J., Goldman L., Odden M.C., Kazi D.S., Bibbins-Domingo K. Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke // Circulation. 2017. 136(12):1087-1098 doi:10.1161/circulationaha.117.027067
12. Kanathur N., Mathai M.G., Byrd R.P. Jr Fields C.L., Roy T.M. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis // Tenn Med., 2001, 94(9):339-41.
13. Kasichayanula S., Chang M., Liu X., Shyu W.C., Griffen S.C., LaCreta F.P., Boulton D.W. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin // Adv Ther. 2012. 29(2). 163-77. doi:10.1007/s12325-011-0098-x.
14. Khan S., Khan I., Novak M., Regmi A., Difilippo W. The Concomitant Use of Atorvastatin and Amlodipine Leading to Rhabdomyolysis // Cureus. 2018. 10(1):e2020. doi:10.7759/cureus.2020
15. Khokhlov A.A., Sychev D.A., Sirotkina A.M., Aspects of safe use of statins: inter-drug interaction, pharmacogenetic issues // Universum: Medicine and pharmacology: electronic scientific journal. 2016. 24. http://7universum.ru/med/article/item/2950.
16. Lennernäs H., Clinical pharmacokinetics of atorvastatin // Clinical Pharmacokinetiks. 2003. 42(13):1141-60. doi:10.2165/00003088-200342130-00005
17. Lewin J.J., Nappi J.M., Taylor M.H. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann Pharmacother. 2002. 36(10): 1546-1549 doi:10.1345/aph.1A481
18. Li D.Q., Kim R.B., McArthur E., Fleet J.L., Hegele R.A., Shah B.R., Weir M.A., Molnar A.O., Dixon S., Tu J.V., Anand S., Garg A.X. Statin Safety in Chinese: A Population-Based Study of Older Adults // PLoS One 2016. 8;11(3):e0150990. doi:10.1371/journal.pone.0150990.
19. Lin J., Zhang Y., Zhou H., Wang X., Wang W., CYP2C9 Genetic Polymorphismis a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy // Clin Lab. 2015. 61(9): 1317-24.
20. Martinez-Jiménez C., Cruz-Angeles J., Videa M., Martínez L.M. Co-Amorphous Simvastatin-Nifedipine with Enhanced Solubility for Possible Use in Combination Therapy of Hypertension and Hypercholesterolemia // Molecules. 2018. 28; 23(9). doi:10.3390/molecules23092161
21. Methaneethorn J., Chamnansua M., Kaewdang N., Lohitnavy M. A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans // Conf Proc IEEE Eng Med Biol Soc. 2014. 5711-4. doi:10.1109/EMBC.2014.6944924.
22. Molden E., Skovlund E., Braathen P. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors // Drug Saf. 2008. 31(7):587-96. doi:10.2165/00002018-200831070-00004
23. Morival C., Westerlynck R., Bouzillé G., Cuggia M., Le Corre P. Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining // Eur J ClinPharmacol. 2018. 74(4):525-534. doi:10.1007/s00228-017-2400-6.
24. Mussina A.Z., Smagulova G.A., Veklenko G.V. Tleumagambetova B.B., Seitmaganbetova N.A., Zhaubatyrova A.A., Zhamaliyeva L.M. Effect of an educational intervention on the number potential drug-drug interactions // Saudi Pharmaceutical Journal. 2019. 27(5). 717-723. https://doi.org/10.1016/j.jsps.2019.04.007.
25. Prom R., Umscheid C.A., Kasbekar N., Spinler S.A. Effect of simvastatin-amiodarone drug interaction alert on appropriate prescribing // Am J Health Syst Pharm. 2013. 70(21). 1878-1879. doi:10.2146/ajhp120553.
26. Ramkumar S., Raghunath A., Raghunath S. Statin Therapy: Review of Safety and Potential Side Effects // Acta.Cardiol.Sin. 2016. 32 (6):631-639.
27. Rätz Bravo A.E., Tchambaz L., Krähenbühl-Melcher A., Hess L., Schlienger R.G., Krähenbühl S. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy // Drug Saf. 2005. 28(3). 263-275. doi:10.2165/00002018-200528030-00007
28. Roten L., Schoenenberger R.A., Krähenbühl S., Schlienger R.G. Rhabdomyolysis in association with simvastatin and amiodarone // Ann Pharmacother. 2004. 38(6). 978-981. doi:10.1345/aph.1D498.
29. Selva-O'Callaghan A., Alvarado-Cardenas M., Pinal-Fernández I., Trallero-Araguás E., Milisenda J.C., Martínez M.Á., Marín A., Labrador-Horrillo M., Juárez C., Grau-Junyent J.M. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations // Expert Rev ClinImmunol. 2018. 14(3): 215-224. doi:10.1080/1744666x.2018.1440206.
30. Shaik A.N., Bohnert T., Williams D.A., Gan L.L., LeDuc B.W. Mechanism of Drug-Drug Interactions Between Warfarin and Statins // J PharmSci. Jun. 2016. 105(6). 1976-1986. doi: 10.1016/j.xphs.2016.03.011.
31. Simonson S.G., Martin P.D., Mitchell P.D. et al., Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics // J Clin Pharmacol. 2005. 45(8). 927-934. doi:10.1177/0091270005278224.
32. Son H., Lee D., Lim L.A., Jang S.B., Roh H., Park K. Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine // Drug Metab Pharmacokinet. 2014. 29(2). 120-8.
33. Srinivas N.R. Dual drug interactions via P-glycoprotein (P-gp)/ cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil // Eur J Clin Pharmacol. 2008. 64(11):1135-6. doi:10.1007/s00228-008-0512-8
34. Sychev D.A., Otdelenov V.A. Inter-Drug interactions in internist's practice: view of clinical pharmacologist. 2014. 12. 18-21. [Russian].
35. Sychev D.A., Otdelenov V.A., Krasnova N.M., Ilyina E.S. Polypragmasy: a clinical pharmacologist’s view // Ter. Arkh. 2016. 88 (12). 94–102. [Russian] doi:10.17116/terarkh2016881294-102.
36. Wilke R.A., Fanciullo J., Point-Counterpoint: SLCO1B1 Genotyping for Statins // S D Med. 2017. 70(3). 102-104.
37. Willrich M.A., Hirata M.H., Hirata R.D. Statin regulation of CYP3A4 and CYP3A5 expression // Pharmacogenomics. 2009. 10(6). 1017-1024. doi: 10.2217/pgs.09.42.
38. Wojtczak A, Skretkowicz J. The role of genetic polymorphisms of cytochrome P450 in drug metabolism used in the treatment of cardiovascular diseases // Kardiologia Polska. 2009. 67(9):1011-4.
39. Wooten J.M. A Brief Drug Class Review: Considerations for Statin Use, Toxicity, and Drug Interactions // SouthMed J. 2018. 111(1):39-44. doi:10.14423/smj.0000000000000752.
40. Yamazaki S. Relationships of Changes in Pharmacokinetic Parameters of Substrate Drugs in Drug-Drug Interactions on Metabolizing Enzymes and Transporters // J Clin Pharmacol. 2018. 3. doi:10.1002/jcph.1104.
41. Yan Y.L., Qiu B., Hu L.J., Jing X.D., Liu Y.J., Deng S.B., Du J.L., She Q. Efficacy and safety evaluation of intensive statin therapy in older patients with coronary heart disease: a systematic review and meta-analysis // Eur J Clin Pharmacol. 2013. 69(12):2001-9. doi:10.1007/s00228-013-1570-0.
Number of Views: 70
Category of articles:
Original articles
Bibliography link
Tuleutayeva R.Ye., Makhatova A.R., Kassymkan A.Ye., Zhumatay A.B., Kakytayeva A.E. The issues of drug interaction in combination pharmacotherapy in cardiological practice // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 4, pp. 42-48. doi 10.34689/SH.2023.25.4.005Related publications:
ANALYSIS OF CLINICAL AND DEMOGRAPHIC INDICATORS OF PATIENTS WITH PARKINSON'S DISEASE IN THE SOUTHERN REGION OF KAZAKHSTAN
A COMPARATIVE STUDY OF DRUG POLICY REGARDING ORPHAN DISEASES IN THE USA, THE EUROPEAN UNION, AND THE REPUBLIC OF KAZAKHSTAN
MUTATIONS IN CARDIAC ION CHANNEL GENES IN KAZAKHSTANI PATIENTS WITH LONG QT SYNDROME
GENETIC FEATURES OF CONGENITAL DYSFUNCTION OF THE ADRENAL CORTEX CAUSED BY 21-HYDROXYLASE DEFICIENCY IN PERSONS OF KAZAKH NATIONALITY
NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE USING THE EXAMPLE OF AKTOBE PATIENTS